CMS Releases the 2019 MPFS and QPP Final Rules

Holland & Knight LLP

Holland & Knight LLP


  • The Centers for Medicare & Medicaid Services (CMS) has published the Calendar Year (CY) 2019 Final Rule for the Medicare Physician Fee Schedule (PFS), which includes provisions related to Medicare physician payments as well as regulations for the Quality Payment Program (QPP).
  • Among notable changes, CMS finalized policies that would reduce provider reimbursement rates for new drugs under Medicare Part B, increase access to telehealth services, and revise a controversial evaluation and management proposal.

The Centers for Medicare & Medicaid Services (CMS) on Nov. 1, 2018, published the Calendar Year (CY) 2019 Final Rule for the Medicare Physician Fee Schedule (PFS). Although in previous years regulations for the Quality Payment Program (QPP) were released independently, the 2019 Medicare PFS Final Rule includes provisions related to Medicare physician payments as well as the QPP. The MPFS dictates Medicare rates and policies under Part B, while the QPP implements two key value-based payment programs: the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APMs).

Most of the provisions of the Final Rule take effect on Jan. 1, 2019; however, CMS pushed the start date until CY 2021 for certain burden reduction proposals in response to concerns from stakeholders.

CMS noted throughout the Final Rule that it wanted to continue to provide physicians and other healthcare practitioners relief from excessive regulation and to reduce compliance needs that interfered with patient care. However, with the QPP, International Pricing Index Model and other demonstrations, that remains to be seen.

Among notable changes, CMS finalized a policy that would reduce provider reimbursement rates for new drugs under Medicare Part B by 3 percent during the first quarter of sales when the average sales price (ASP) is unavailable. The Trump Administration first floated the change in its fiscal 2019 budget proposal released in February 2018, and the idea previously had been recommended by the Medicare Payment Advisory Committee (MedPAC)in its June 2017 Report to the Congress. CMS did not provide an estimate of how much the new policy would be expected to reduce Medicare expenditures.

The Final Rule also includes increased access to telehealth services. Specifically, CMS finalized distinguishing between Medicare telehealth services and "communication technology-based and remote evaluation services." This distinction would permit Medicare reimbursement for services that do not meet the statutory requirements for Medicare-reimbursable telehealth services. Ultimately, CMS finalized paying clinicians for virtual check-ins and for evaluations made from patient-submitted photos/images ("store and forward applications.") With CMS clearly warming to telehealth, Congress may not be too far behind.

Additionally, CMS scaled back and delayed for two years proposed changes to overhaul Medicare billing practices that have been in place for routine office visits since 1995.Instead of finalizing the blended rates for evaluation and management (E/M) codes for CY 2019 and 2020, CMS is implementing changes to the documentation policy but maintaining the current payment structure. However, starting in CY 2021 and beyond, CMS will change the payment structure by paying a single rate for E/M office visit Levels 2 through 4 for established and new patients, while maintaining the payment rate for E/M office visit Level 5.

Visit the CMS website for its MPFS Fact Sheet and QPP Fact Sheet.

Final Rule Highlights

Medicare Physician Fee Schedule (PFS) Updates

General Payment and Relative Value Unit (RVU) Updates: The finalized 2019 MPFS conversion factor is $36.046, a slight increase above the 2018 MPFS conversion factor of $35.9996. CMS added practice experience (PE) utilization data for two new specialties: 1) Hospitalists and 2) Advanced Heart Failure and Transplant Cardiology.

Update to Wholesale Acquisition Cost (WAC)-Based Payment for Part B Drugs: While most Part B drugs are paid at Average Sales Price (ASP) plus 6 percent of ASP, certain drugs are currently paid at WAC plus 6 percent until more data is available (generally by the third quarter). CMS finalized a proposal to reduce these payments to WAC plus 3 percent and allow Medicare Administrative Contractors the authority to pay at WAC plus 3 percent as well. CMS notes that this policy is consistent with recent recommendations from MedPAC.

Evaluation and Management (E/M) Visits: Instead of finalizing the blended rates for E/M codes for CY 2019 and 2020, CMS is implementing changes to the documentation policy but maintaining the current payment structure,affording stakeholders additional time to engage with the agency. For CY 2019 and beyond, CMS finalized the below policies.

  • It eliminated the requirement to document the medical necessity of a home visit in lieu of an office visit.
  • For office/outpatient visits for established patients, when relevant information is already contained in the medical record, physicians can focus their documentation on what has changed since the last visit, or on pertinent items that have not changed.
  • For E/M office visits for new and established patients, physicians can indicate they reviewed and verified the information, so they do not need to re-enter in the medical record information on the patient's chief complaint and history that has already been entered by ancillary staff or the beneficiary.
  • CMS removed potentially duplicative requirements for notations in medical records that may have previously been included in the medical records by residents or other members of the medical team for E/M visits furnished by teaching physicians.

Starting in CY 2021 and beyond, CMS will make the following changes to the payment structure.

  • CMS will collapse code Levels 2 through 4 into one level and will pay providers a single rate (one each for established and new patients), but it will maintain the Level 5 code, which accounts for care provided to the most complex patients. CMS had originally proposed folding the Level 5 code into the single rate.
  • CMS estimates that, once the new payment policies are implemented in 2021, it will disproportionally benefit specialties that report lower-level visits, such as podiatry (+10 percent), as well as specialties that report E/M visits in conjunction with minor procedures, such as dermatology (+4 percent).
  • The change in the proposal to maintain a Level 5 visit for highly complex patients mitigates the estimated impacts on specialties that report many highly complex visits, such as allergy/immunology (was -5 percent, now 0 percent), hematology/oncology (was -4 percent, now 0 percent) and rheumatology (was -4 percent, now -1 percent).
  • Physicians will also have the option to receive higher rates with the creation of a new "extended visit" code to account for additional time spent with patients whose visits are coded at Levels 2 through 4.
  • The agency also said, beginning CY 2021, it will allow clinicians to rely more on their own medical decision-making or the time spent with a patient to determine the level of a patient's care needs.

Further, in response to comments from external stakeholders, CMS will not finalize the following proposals:

  • reduced payment for E/M services that are furnished on the same day as procedures
  • separate coding and payment for podiatric E/M visits
  • standardized allocation of practice expense relative value units (RVUs) for the codes that describe these services

Telehealth Updates: CMS finalized a policy to add separate Medicare reimbursement for two types of services:

  1. Brief Communication Technology-Based Service (HCPCS Code: G2012), e.g., Virtual Check-In. Virtual check-ins are "brief check-in services furnished using communication technology that is used to evaluate whether or not an office visit or other service is warranted." Under CMS' regulation, virtual check-ins would be eligible for separate payment, but these services would not be billable if they originated from or led to another, related E/M service by the same physician or qualified health care professional within the previous seven days, or led to an E/M service or procedure within the next 24 hours or soonest available appointment.
  2. Remote Evaluation of Recorded Video and/or Images Submitted by the Patient (HCPCS Code: G2010). Like virtual check-ins, these "store and forward" services would not be billable if they originated from or led to another, related E/M service by the physician or qualified health care professional within the previous seven days, or led to an E/M service or procedure within the next 24 hours or soonest available appointment. G2010 may be billed only for established patients. CMS finalized that the follow-up with the patient could take place via phone call, audio/video communication, secure text messaging, email or patient portal communication. CMS also finalized that beneficiary consent may be verbal or written, including electronic confirmation that is noted in the medical record for each billed service for HCPCS code G2010.

The communication technology-based and remote evaluation services do not satisfy the requirements for Medicare telehealth services as set forth in Section 1834(m) of the Social Security Act, 42 U.S.C. §1395m(m), but in the Final Rule, CMS takes the view that the Medicare telehealth standards do not apply to services that "inherently involve the use of communication technology."

CMS also finalized adding prolonged preventive services (HCPCS Codes G0513 and G0514) to the list of Medicare telehealth services that can be reimbursed when provided via telehealth and in compliance with CMS' reimbursement requirements for telehealth services, including originating site restrictions and geographic requirements.

CMS also finalized policies to pay separately for new codes describing chronic care remote physiologic monitoring (CPT codes 99453, 99454 and 99457) and interprofessional internet consultation (CPT codes 99451, 99452, 99446, 99447, 99448 and 99449).

In addition, beginning July 1, 2019, CMS will increase access to telehealth services for opioid use disorder treatment by removing the originating site geographic requirements and allowing providers to be reimbursed for telehealth services originating in an individual's home for the treatment of a substance use disorder or a co-occurring mental health disorder.

Off-Campus Provider-Based Hospital Department Payments (Section 603): For non-excepted departments paid under the MPFS, CMS maintained its CY 2018 payment Relativity Adjuster of 40 percent of the amount that would have been paid under the Hospital Outpatient Prospective Payment System. This is a decrease from the 50 percent rate in CY 2017.CMS states that this methodology will continue to be standard practice until an alternative payment method is proposed and finalized through rulemaking.

Imaging Appropriate Use Criteria (AUC) Program: Implementation of AUC is set to begin in 2020, with reimbursement penalties for imaging starting in 2021.

CMS finalized its proposed revision to the significant hardship criteria to include criteria related to internet access, vendor issues, and extreme or uncontrollable circumstances. In addition, CMS added independent diagnostic testing facilities (IDTFs) to the definition of applicable settings, allowing the AUC program to be more consistently applied to outpatient settings. CMS also finalized that only auxiliary staff "working under the direction of the ordering professional" can consult CDS.

CMS also clarified that exceptions granted for an individual with an emergency medical condition includes instances where an emergency medical condition is suspected but not yet confirmed. CMS noted this might include, for example, instances of severe pain or severe allergic reactions. In these instances, the exception is applicable even if it is determined later that the patient did not, in fact, have an emergency medical condition.

Clinical Laboratory Fee Schedule (CLFS): CMS finalized its proposal to change the definition of "applicable laboratories" that must report data for the purposes of weighted median payment calculations as implemented following the Protecting Access to Medicare Act (PAMA). The change would modify the definition of an applicable laboratory to exclude Medicare Advantage (MA) plan payments from total Medicare revenues, the denominator of the majority of Medicare revenues threshold.

Changes to Medicare Shared Savings Program (MSSP) Accountable Care Organization (ACO) Quality Measure Set: The Final Rule included several changes to the MSSP program beyond those included in a separate rule proposed in August. To reduce reporting burden and align MSSP with the Merit-Based Incentive Payments System (MIPS), CMS finalized removal of 10 quality measures and added two quality measures for the payment year (PY) 2019 MSSP quality measure set. The rule also allows beneficiaries who voluntarily align with a nurse practitioner, physician assistant, certified nurse specialist or a physician with a specialty not used in assignment to be prospectively assigned to an ACO if the clinician they align with is participating in an ACO. The Final Rule also revises the definition of primary care services used in the beneficary assignment.

Six-Month Extension to Subset of MSSP ACOs: To address time-sensitive proposals to the MSSP timeline as described in the MSSP ACO Pathway to Success proposed rule, CMS finalized its proposal to grant ACOs whose participation ends Dec. 31, 2018, a six-month voluntary extension from Jan 1, 2019, to June 30, 2019.

Request for Information on Price Transparency: In the Proposed Rule,CMS requested information on price transparency. Although the Proposed Rule did not set forth any specific proposals, CMS stated that it was considering potential actions to promote provider-side efforts "to engage in consumer-friendly communication of their charges" so that patients understand their potential financial liability for services and can compare charges between providers. The agency sought information regarding barriers preventing providers and suppliers from informing patients of their out-of-pocket costs; what changes are needed to support greater transparency around patient obligations for their out-of-pocket costs; what can be done to better inform patients of these obligations; and what role providers of healthcare services and suppliers should play in this initiative. This request for information was also included in the FY 2019 Inpatient Prospective Payment System (IPPS) Proposed Rule.

In the Final Rule, CMS noted that it received 94 responses and will continue to consider the issue. CMS has separately proposed price transparency requirements for direct-to-consumer advertising.

Signature Requirements in Certain Compensation Arrangement Exceptions to the Physician Self-Referral Law: CMS finalized refining the self-referral (Stark) regulations to tighten and clarify the existing law with respect to what qualifies as a written agreement and when a signature must be secured. Specifically, it added regulatory provisions specifying that 1) the writing requirement contained in various compensation arrangement exceptions can be satisfied by "a collection of documents, including contemporaneous documents evidencing the course of conduct between the parties" and 2) the signature requirement can be satisfied if the compensation arrangement meets all of the other requirements of the exception and if the required signatures are obtained within "90 consecutive calendar days immediately following the date" a signature was required but not yet secured. Lastly, CMS includes the final annual update of the list of Current Procedural Terminology (CPT)/Healthcare Common Procedure Coding System (HCPCS) codes that are included in the scope of designated health services to which the Physician Self-Referral Law applies.

Quality Payment Program (QPP) Updates

This year's QPP Final Rule continues to slightly ramp up the Merit-Based Incentive Payment System (MIPS) for eligible clinicians, with CMS increasing the number of clinicians included in MIPS, increasing the threshold score for avoiding a MIPS penalty and increasing the weight of the MIPS cost component.

Advanced Alternative Payment Models (APMs) track policies remained fairly status quo, with some slight policy changes intended to streamline the program and reduce burden for participants.

MIPS Flexibility and Changes: CMS advances minimal changes to the existing MIPS program, affecting the cost, quality and interoperability components.

CMS finalized reweighting the MIPS categories to 45 percent Quality, 25 percent Promoting Interoperability, 15 percent Cost, and 15 percent Improvement Activities.

  • For Quality, CMS finalized the removal of 26 measures (of 34 proposed) from the MIPS program in alignment with the "Meaningful Measures" initiative by removing process-based quality measures that are low-value or low-priority.
  • For Cost, CMS finalized eight episode-based treatment groups into the calculation of the cost category addressing acute and procedural episodes. Currently, the cost category is based on two measures: Total Per Capita Cost and Medicare Spending Per Beneficiary. The eight recently developed, episode-based cost measures include: Elective Outpatient Percutaneous Coronary Intervention (PCI), Knee Arthroplasty, Revascularization for Lower Extremity Chronic Critical Limb Ischemia, Routine Cataract Removal with Intraocular Lens (IOL) Implantation, Screening/Surveillance Colonoscopy, Intracranial Hemorrhage or Cerebral Infarction, Simple Pneumonia with Hospitalization, and ST-Elevation Myocardial Infarction (STEMI) with Percutaneous Coronary Intervention (PCI). Eligible clinicians may have concerns about an increase in the weight of the cost category to 15 percent in the same year that new episode-based measures may be in effect.
  • For Improvement Activities, CMS removed one previously existing improvement activity, added six new improvement activities (addressing eye exams, navigation, care management, communication, education and patient safety), and modified five improvement activities.
  • For Promoting Interoperability (formerly Advancing Care Information), CMS eliminated the base, performance and bonus scores, and finalized a new scoring methodology,but maintains the "all-or-nothing" scoring. CMS will use performance-based scoring at the individual measure level. Each measure would be scored based on the performance on the measure on the submission of a numerator and a denominator, or yes or no. The scores for each individual measure would be added together to calculate the score of up to 100 possible points.

CMS is creating four overall objectives: e-Prescribing, Health Information Exchange, Provider to Patient Exchange, and Public Health and Clinical Data Exchange. It is also adding two new measures to the e-Prescribing objective: Query of Prescription Drug Monitoring Program (PDMP) and Verify Opioid Treatment Agreement.

CMS also finalized requiring MIPS-eligible clinicians to use 2015 Edition-certified Electronic Health Records (EHRs). Currently, clinicians can use 2014-certified systems to be eligible for the program.

Performance Period: The performance period for the Quality and Cost categories remains at the full performance year. It remains at 90 days for the Promoting Interoperability and Improvement Activities categories.

Low-Volume Threshold: To be excluded from MIPS, clinicians or groups would need to meet one of the following three criteria: have $90,000 or less in Part B allowed charges for covered professional services, provide care to 200 or fewer beneficiaries, or provide 200 or fewer covered professional services under the PFS (added criterion).

MIPS Payment Adjustment/Performance Threshold: The "performance threshold" represents the score that is necessary to receive a neutral to the positive payment adjustment for the year. A score below the performance threshold will result in a negative payment adjustment, while a score above the payment threshold will result in a positive payment adjustment. A score at the payment threshold will result in a neutral payment adjustment. CMS increased the performance threshold from 15 points to 30 points (out of 100). The exceptional performance threshold is set at 75 points, rather than the proposed 80 points, up from 70 points in 2018.

Expanding QPP Eligibility/Opt-In: CMS finalized an additional exclusion eligibility threshold for providers who do not submit at least 200 claims for the covered professional services under the PFS. CMS also said it would permit clinicians or groups who meet some but not all of these eligibility thresholds to opt-in to MIPS.

The agency also proposes expanding the types of clinicians eligible to participate in MIPS. Currently, five types of clinicians are eligible to participate: certified registered nurse anesthetists, clinical nurse specialists, nurse practitioners, physicians and physician assistants. Those clinicians could also qualify as part of a group. For 2019, CMS is expanding the eligibility pool to include physical therapists, occupational therapists, clinical psychologists, and registered dietitians or nutrition professionals.

Facility-Based Measurement: CMS finalized the implementation of a facility-based MIPS scoring that would allow "facility-based clinicians" to use the Hospital Value-Based Purchasing Program performance for the MIPS Quality and Cost categories. Clinicians who provide 75 percent or more of their services in an inpatient hospital, outpatient hospital or ED setting are eligible for facility-based measurement under MIPS.

New Medicare Advantage Qualifying Payment Arrangement Incentive (MAQI) Demonstration: CMS finalized a five-year demonstration to test whether exempting clinicians who participate in certain Medicare Advantage payment arrangements would increase participation in Advanced APMs (AAPM). Participants who meet the requirements of this demonstration would automatically be exempt from MIPS, but would not receive the AAPM's 5 percent bonus.

Changes to Other Payer AAPM Criteria: CMS modified the Certified Electronic Health Record Technology (CEHRT) criteria for Other Payer AAPMs so that, beginning in 2020, 75 percent (instead of 50 percent) of eligible clinicians in other payer arrangements must use CEHRT. In addition, CMS finalized that in 2020 at least one of the quality measures used in other payer arrangements must be finalized on the MIPS final list of measures, endorsed by a consensus-based entity, or determined by CMS to be evidence-based, reliable and valid.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Holland & Knight LLP | Attorney Advertising

Written by:

Holland & Knight LLP

Holland & Knight LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.